Informed Prostate Cancer Patient Support

Ac-225 rosopatamab tetraxetan shows promising activity in Lu-PSMA–pretreated mCRPC | Urology Times Advanced Therapy Watch Informed Prostate Cancer Support Group Newsletter — Advanced & Metastatic Disease Series BLUF (Bottom Line Up Front):   At the 2026 ASCO Annual Meeting, Convergent Therapeutics reported interim Phase 2 results from Part 3 of the CONVERGE-01 trial testing Ac-225 rosopatamab tetraxetan (CONV01-α), an alpha-particle-emitting radioantibody, in men with metastatic castration-resistant prostate cancer (mCRPC) whose disease had already progressed after Lu-177-PSMA radioligand therapy — a population with no established standard of care. Among 35 treated patients, 40% of those evaluable for PSA response achieved a decline of 50% or more, with the best durability seen at the intended Phase 3 target dose (median radiographic progression-free survival of 8.41 months). Side effects were mostly blood-count related and manageable; there was no kidney toxi...

Proton Therapy for Prostate Cancer: Key Takeaways Proton Therapy vs. IMRT for Prostate Cancer: What the Evidence, the Guidelines, and the Courts Say Now Informed Prostate Cancer Support Group (IPCSG) Newsletter — Patient Education Series — July 2026 BLUF (Bottom Line Up Front):   For most men with newly diagnosed low- or intermediate-risk localized prostate cancer, the best available randomized evidence — the phase III PARTIQoL trial — shows that proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT) produce statistically indistinguishable outcomes: roughly 93–94% five-year progression-free survival with both, and no meaningful difference in bowel, urinary, sexual, or hormonal side effects. Proton therapy typically costs substantially more, and insurers have been repeatedly sued — and have paid multimillion-dollar settlements — over improper denials, even though the treatments perform similarly for the average patient. The more promising, still-e...

Recent Developments in Prostate Cancer | MedPage Today A roundup of the practice-shaping trial data reported between February and June 2026 — ASCO GU, AUA, and the ASCO Annual Meeting — prepared for the IPCSG community BLUF — Bottom Line Up Front Six studies reported in the first half of 2026 collectively push treatment earlier and make it more precisely targeted to tumor biology. For men with high-risk localized disease, adding a year of apalutamide around surgery cut the risk of metastasis by 20% (PROTEUS). For men with hormone-sensitive metastatic disease carrying DNA-repair gene mutations, adding a PARP inhibitor (talazoparib) to enzalutamide cut progression risk by roughly half (TALAPRO-3). Darolutamide continues to distinguish itself on two fronts — real-world-comparable efficacy against a historical ADT-alone benchmark (ARASEC) and measurably less cognitive decline than enzalutamide (ARACOG). In first-line metastatic castration-resistant disease with BRCA1...